Bristol-Myers Squibb Co
BRM
Company Profile
Business description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
32,500
Stocks News & Analysis
stocks
Bapcor earnings: Under review amid sharply lower profits and a massively dilutive equity raise
Our view of results.
stocks
Earnings winners: WOW, WTC and FMG set the tone
The ASX companies that closed out earnings season with a bang.
stocks
Do dividends build or limit wealth creation?
In this episode of Investing Compass, we talk to James Gruber about why he dislikes dividend stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,435.60 | 15.10 | 0.16% |
| CAC 40 | 8,617.64 | 3.29 | -0.04% |
| DAX 40 | 25,344.70 | 55.68 | 0.22% |
| Dow JONES (US) | 49,499.20 | 17.05 | 0.03% |
| FTSE 100 | 10,900.27 | 53.57 | 0.49% |
| HKSE | 26,630.54 | 249.52 | 0.95% |
| NASDAQ | 22,878.38 | 273.69 | -1.18% |
| Nikkei 225 | 58,850.27 | 96.88 | 0.16% |
| NZX 50 Index | 13,722.97 | 52.26 | 0.38% |
| S&P 500 | 6,908.86 | 37.27 | -0.54% |
| S&P/ASX 200 | 9,198.60 | 16.90 | 0.18% |
| SSE Composite Index | 4,162.88 | 16.25 | 0.39% |